April 18, 2011
PRESS RELEASE
PEGASUS ACQUIRES U.S. PATENT FOR ITS HEARTVUE 6S SCREENING DEVICE; APPOINTS TWO EUROPEAN DISTRIBUTORS.
 |
|
November 3rd, 2008
PRESS RELEASE
PEGASUS COMPLETES RESEARCH & DEVELOPMENT OF NEW, NON-INVASIVE HEARTVUE MONITORING SYSTEM FOR EMERGENCY ROOM ENVIRONMENTS.
|
|
October 8th, 2008
PRESS RELEASE
PEGASUS COMPLETES FIRST PHASE TESTING OF NON-TOXIC, ENVIRONMENTALLY-FRIENDLY, MOLD & MILDEW RESISTANT, WATER-BASED PAINT FOR A GROWING $10 BILLION MARKET.
|
|
August 18th, 2008
PRESS RELEASE
CLINICAL STUDIES COMPLETED FOR HEARTVUES 6S SYSTEM HEART SCREENING SYSTEM.
|
|
July 16th, 2008
PRESS RELEASE
NON-TOXIC, BIOLOGICAL ANTI-MOLD & MILDEW PRODUCT DISTRIBUTION AGREEMENT SIGNED BY PEGASUS’ NEW DISTRIBUTOR IN MEXICO.
|
|
June 9th, 2008
PRESS RELEASE
PEGASUS RECEIVES FIRST LARGE PURCHASE ORDER FROM COMMANDER INTERNATIONAL FOR ITS INNOVATIVE, BIOLOGICAL TOXIC MOLD CONTROL PRODUCT.
|
|
March
27, 2008
PRESS RELEASE
PEGASUS FILES PATENTS ON NEW BIOLOGICAL TOXIC MOLD CONTROL PRODUCT, OPENS LAB & APPOINTS DISTRIBUTOR FOR MARKETING TO MULTI-BILLION DOLLAR WORLDWIDE MOLD REMOVAL MARKET.
|
|
December
18, 2007
PRESS RELEASE
HARVARD UNIVERSITY COMPLETES CLINICAL STUDY OF PEGASUS HEARTVUE 6S SYSTEM HEART SCREENING DEVICE.
|
|
January
8, 2007
PRESS RELEASE
PEGASUS ACQUIRES WORLDWIDE MARKETING
RIGHTS TO EFFECTIVE BIOLOGICAL-CONCEPT MOLD REMOVAL
SYSTEM
|
|
November
30 , 2006
PRESS RELEASE
PEGASUS/HEARTVIEW'S SCREENING DEVICE FOR
HEART DISEASE RECEIVES MARKETING APPROVAL FOR
EUROPEAN UNION .
|
|
October
30 ,
2006
PRESS RELEASE
PEGASUS/HEARTVIEW
TO MARKET ITS HEARTVUE 6S SCREENING DEVICE IN
EUROPE
|
|
June 27,
2006
PRESS RELEASE
PEGASUS/HEARTVIEW
DELIVERS FIRST SHIPMENT OF 55 HEARTVUE 6S SYSTEM
ELECTROCARDIOGRAPH UNITS TO CHINA
|
|
March 9th, 2006
PRESS RELEASE
PEGASUS/HEARTVIEW DEMONSTRATES HEARTVUE™ 6S
SYSTEM CAPABILITIES AT THE ACC 55TH SCIENTIFIC
SESSION EXPOSITION IN ATLANTA, MARCH 11TH TO MARCH
14TH
(Booth #1855)
|
|
February
9th, 2006
PRESS RELEASE
PEGASUS/HEARTVIEW
SIGNS MULTI-YEAR SALES AGREEMENT WITH CHINA FOR
ITS GROUND-BREAKING HeartVue™ 6S SYSTEM TECHNOLOGY.
Deliveries
Of The Company's Non-Invasive Heart Screening
System Are Expected To Exceed $ 50 Million USD.
|
|
|
|
April
12, 2005
PRESS RELEASE:
PEGASUS/HEARTVIEW CLINICAL TRIAL FOR HEART DISEASE SCREENING DEVICE UNDERWAY
IN NEW YORK
|
|
For more information,
please contact:
Daniel P. Kesonen ,
Chairman & CEO
Pegasus Pharmaceuticals Inc.
& Heartview LLC
4400 PGA Blvd., Suite 900 ,
Palm Beach Gardens , FL U.S.A. 33410
Telephone: (561) 626-9901
Email: info@pegasusbiosciences.com
| Issued & Outstanding
Shares: |
30,826,490 |
| Transfer Agent: |
Stalt, Inc.
671 Oak Grove Avenue,
Menlo Park, CA, U.S.A. 94025
(650) 321-7111
|
|
